Form 4: Verona Pharma CFO Mark Hahn Reports Share Transactions Following Vesting of Performance Restricted Share Units

Chief Financial Officer of Verona Pharma, Mark Hahn, reports acquisition and disposal of ordinary shares related to vesting of performance restricted share units and tax obligations.

Summary

• Mark Hahn, the CFO of Verona Pharma, reported changes in his beneficial ownership of the company's ordinary shares.
• On February 1, 2025, he acquired 200,000 ordinary shares upon the vesting of Performance Restricted Share Units related to the first commercial sale of ensifentrine.
• On February 3, 2025, 166,888 ordinary shares were disposed of to satisfy tax withholding obligations related to the vesting of Restricted Share Units and Performance Restricted Share Units at a price of $7.1625 per share.
• Following these transactions, Hahn beneficially owns 13,326,848 ordinary shares.
• These shares include 2,725,000 Ordinary Shares underlying Restricted Share Units and 10,601,848 Ordinary Shares underlying ADSs.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The vesting of shares indicates achievement of a commercial milestone (first sale of ensifentrine), which is positive. The tax-related disposal is a normal part of equity compensation.

Positives

• The vesting of Performance Restricted Share Units indicates a successful milestone for Verona Pharma, specifically the first commercial sale of ensifentrine.

Industry Context

This filing is a routine disclosure related to executive compensation and ownership changes, common in publicly traded companies. It reflects the alignment of executive incentives with company performance, specifically the commercial success of ensifentrine.

Comparison to Industry Standards

• Executive compensation packages often include performance-based equity awards, such as Restricted Share Units and Performance Restricted Share Units, to incentivize executives to achieve specific company goals.
• The vesting of these units upon milestones like the first commercial sale of a product is a standard practice in the pharmaceutical industry.
• Companies like AstraZeneca and GlaxoSmithKline also utilize similar equity-based compensation strategies for their executives.

Stakeholder Impact

• Shareholders may view the vesting of Performance Restricted Share Units positively, as it signals progress in the commercialization of ensifentrine.
• Employees may be motivated by the achievement of company milestones that trigger equity awards.

Key Dates